Cite
HARVARD Citation
Cortes, J. et al. (n.d.). 1802 Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC). European journal of cancer. pp. S265-. [Online].